세계의 정형외과용 골이식편 시장 : 규모, 점유율, 동향 분석(2025-2031년) - MedCore

The global bone graft substitute (BGS) market was valued at approximately $2.83 billion in 2024 and is expected to grow at a CAGR of 4.1%, reaching approximately $3.75 billion by 2031. The market includes various types of bone graft substitutes used in orthopedic, trauma, and reconstructive surgeries.

The BGS market is segmented into:

• Allograft BGS
• Demineralized Bone Matrix (DBM) Allograft BGS
• Synthetic BGS

The market is further categorized based on indication type:

• Spine (Cervical, Thoracolumbar)
• Trauma (Non-union, Fresh Fracture)
• Large Joint Reconstruction (Hip, Knee)
• Craniomaxillofacial
• Oncology
• Foot Bone Reconstructions

Market Insights

• Unit Sales & Average Selling Prices
• Market Size & Growth Trends
• Procedure Numbers
• Market Drivers & Limiters
• Market Forecasts Until 2031
• Recent Mergers & Acquisitions
• Competitive Landscape
• Company Profiles & Product Portfolios

Market Trends

• The COVID-19 pandemic caused a decline in BGS sales due to postponed elective surgeries. However, the market recovered strongly by 2022 and resumed steady growth.
• Minimally invasive techniques are driving the adoption of synthetic and DBM-based grafts over traditional bone grafting procedures.
• Rising orthopedic procedures due to an aging population and increasing trauma-related injuries are fueling market growth.
• Technological advancements in bioengineered bone grafts are increasing graft efficiency and patient outcomes.

Market Share Insights

Top Competitors in the Global Bone Graft Substitute Market (2024):

1 Medtronic

* Market leader due to a dominant share in the DBM and synthetic BGS segments.

* Grafton(R) - The first fiber-based DBM allograft BGS and one of the most widely used.

* MASTERGRAFT(R) - Synthetic BGS product line available in granules, moldable putty, flexible strip, and matrix EXT.

2 Stryker

* Second-largest competitor in the market.

* Offers multiple BGS products including Vitoss(TM), ALLOMATRIX(R), FUSIONFLEX(R), and PRO-STIM(R).

3 DePuy Synthes (Johnson & Johnson)

* Third-largest competitor in the BGS market.

* Competes with its DBX(R) DBM product line and chronOS(R) synthetic BGS.

Global Research Scope

• Regions Covered:

* North America: United States, Canada

* Latin America: Brazil, Mexico, Chile, Colombia

* Western Europe: Germany, France, Italy, Spain, United Kingdom

* Central & Eastern Europe: Poland, Russia, Turkey

* Middle East: Saudi Arabia, UAE, Israel

* Asia Pacific: China, Japan, India, South Korea

* Africa: South Africa, Egypt, Nigeria

• Base Year: 2024
• Forecast Period: 2025-2031
• Historical Data: 2021-2023

Quantitative Coverage

• Market Size
• Market Shares
• Market Forecasts
• Market Growth Rates
• Units Sold
• Average Selling Prices
• Procedure Numbers

Qualitative Coverage

• COVID-19 Impact
• Market Growth Trends
• Market Limiters
• Competitive Analysis & SWOT for Top Competitors
• Mergers & Acquisitions
• Company Profiles
• Product Portfolios
• FDA Recalls
• Disruptive Technologies
• Disease Overviews

Data Sources

• Primary Interviews with Industry Leaders
• Government Physician Data
• Regulatory Data
• Hospital Private Data
• Import & Export Data
• iData Research Internal Database

TABLE OF CONTENT

• 4.1 Executive Summary
  • 4.1.1 Global Orthopedic Bone Graft Substitute Market Overview
  • 4.1.2 Competitive Analysis
  • 4.1.3 Regions Included
• 4.2 Introduction
• 4.3 Procedure Numbers
  • 4.3.1 Total Orthopedic Bone Grafting Procedures
  • 4.3.2 Allograft Procedures
  • 4.3.3 Demineralized Bone Matrix Procedures
  • 4.3.4 Synthetic Procedures
• 4.4 Market Overview
  • 4.4.1 By Segment
  • 4.4.2 By Region
• 4.5 Market Analysis and Forecast
  • 4.5.1 Total Orthopedic Bone Graft Substitute Market
  • 4.5.2 Allograft Bone Graft Substitute Market
  • 4.5.3 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
  • 4.5.4 Synthetic Bone Graft Substitute Market
    • 4.5.4.1 Synthetic Bone Graft Substitute Market by Generation Type
• 4.6 Unit Analysis
  • 4.6.1 Allograft Bone Graft Substitute Unit Analysis
    • 4.6.1.1 Allograft Bone Graft Substitute Units Sold by Indication
    • 4.6.1.1.1 Spine Allograft Bone Graft Substitute Units Sold
    • 4.6.1.1.2 Trauma Allograft Bone Graft Substitute Units Sold
    • 4.6.1.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold
  • 4.6.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Unit Analysis
    • 4.6.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication
    • 4.6.2.1.1 Spine Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
    • 4.6.2.1.2 Trauma Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
    • 4.6.2.1.3 Large Joint Reconstruction Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold
  • 4.6.3 Synthetic Bone Graft Substitute Unit Analysis
    • 4.6.3.1 Synthetic Bone Graft Substitute Units Sold by Indication
    • 4.6.3.1.1 Spine Synthetic Bone Graft Substitute Units Sold
    • 4.6.3.1.2 Trauma Synthetic Bone Graft Substitute Units Sold
    • 4.6.3.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold
• 4.7 Drivers and Limiters
  • 4.7.1 Market Drivers
  • 4.7.2 Market Limiters
• 4.8 Competitive Market Share Analysis